Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3BNC117-LS + 10-1074-LS + N-803
- Development stage
- Unknown
- Lead developer
- The Rockefeller University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
3BNC117-LS + 10-1074-LS + N-803 is an experimental combination therapy being investigated for the treatment and potential cure of HIV-1 infection. This regimen utilizes a 'shock and kill' strategy: N-803 (nogapendekin alfa inbakicept), an IL-15 superagonist complex, acts as a latency-reversing agent to 'shock' latent HIV out of infected cells while simultaneously activating natural killer (NK) cells and CD8+ T cells. The two long-acting broadly neutralizing antibodies (bnAbs), 3BNC117-LS and 10-1074-LS, then 'kill' the virus by neutralizing free virions and targeting infected cells for antibody-dependent cellular cytotoxicity (ADCC). 3BNC117-LS targets the CD4 binding site of the HIV-1 envelope glycoprotein gp120, while 10-1074-LS targets the V3 loop glycan-dependent epitope. The combination is currently being evaluated in Phase 1 clinical trials sponsored by Rockefeller University in collaboration with ImmunityBio.
- Other names
- nogapendekin alfa inbakiceptAnktiva
02
Targets
IL2RB (IL-2 receptor beta chain)gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on 3BNC117-LS + 10-1074-LS + N-803.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3BNC117-LS + 10-1074-LS + N-803.